{"database": "lobbying", "table": "lobbying_activities", "rows": [[2189209, "7902221c-3005-4343-b5b7-1464f5398b6e", "Q3", "THE D MAJOR GROUP", 401103162, "ALLERGAN INC (FORMERLY ACTAVIS INC )", 2018, "third_quarter", "PHA", "Monitor issues concerning bioequivalence standards for pharmaceuticals.", "HOUSE OF REPRESENTATIVES,SENATE,White House Office", 50000, null, 0, 0, "2018-10-17T17:16:37.977000-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["2189209"], "units": {}, "query_ms": 1.8528420478105545, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}